


Huakang Biomedical focuses on assisted reproductive treatment market

31 October 2019 | News

Signs MOU with a World Leading Fertility Group Endeavors



Huakang Biomedical Holdings Company Limited is pleased to announce that Huakang Biomedical Company Limited, a direct wholly-owned subsidiary of the Group, entered into a Memorandum of Understanding (MOU) with a Joint Venture Partner in relation to the establishment of the Joint Venture Company in Hong Kong for the research, development and registration of technology, devices and products for assisted reproductive treatment (ART) in the People's Republic of China (PRC); and the sale and export of devices and products in the PRC, countries in Asia Pacific Region and other territories.

Based in Australia, the Joint Venture Partner Group has over 30 years of experience in the field of fertility treatments and is one of Australia's leading fertility groups offering fully integrated assisted reproductive treatment and clinical services as well as devices and products applied with technologies in assisted reproduction treatment.

The MOU was entered against the background of the rising per capita income as well as the increasing prevalence of infertility in the cities of PRC. Likewise, the policies of PRC Government favour the growth of the ART market. In the light of these favourable factors, Huakang Biomedical hopes to form strategic alliance with overseas leading fertility group to create synergy along the supply chain of the ART market.